SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/23/22 Brooklyn ImmunoTherapeutics, Inc. 8-K:5 9/21/22 10:171K Broadridge Fin’l So… Inc |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 42K 5: R1 Document and Entity Information HTML 47K 8: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- brhc10042191_8k_htm XML 15K 7: EXCEL IDEA Workbook of Financial Reports XLSX 8K 3: EX-101.LAB XBRL Labels -- btx-20220921_lab XML 63K 4: EX-101.PRE XBRL Presentations -- btx-20220921_pre XML 45K 2: EX-101.SCH XBRL Schema -- btx-20220921 XSD 14K 9: JSON XBRL Instance as JSON Data -- MetaLinks 13± 19K 10: ZIP XBRL Zipped Folder -- 0001140361-22-034533-xbrl Zip 14K
i Delaware
|
i 31-1103425
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
i 10355 Science Center Drive, i Suite 150
|
||
i San Diego, i California
|
i 92121 |
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
i Common Stock, par value $0.005 per share
|
i BTX
|
i The Nasdaq Stock Market LLC
|
Emerging growth company i ☐
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Director
|
Votes
For
|
Votes
Withheld
|
Broker
Non-Votes
|
|||
Charles Cherington
|
24,960,908
|
3,213,277
|
14,849,874
|
|||
Matthew Angel
|
26,060,381
|
2,113,804
|
14,849,874
|
|||
Nicholas J. Singer
|
26,037,962
|
2,136,223
|
14,849,874
|
|||
Gregory Fiore
|
25,923,220
|
2,250,965
|
14,849,874
|
|||
William Wexler
|
26,044,952
|
2,129,233
|
14,849,874
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
23,660,694
|
4,462,421
|
51,070
|
14,849,874
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
42,584,506
|
373,779
|
65,774
|
—
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
40,383,795
|
2,603,310
|
36,954
|
—
|
Brooklyn ImmunoTherapeutics, Inc.
|
||
Dated: September 23, 2022
|
By:
|
/s/ Andrew Jackson
|
Chief Financial Officer
|
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 9/23/22 | |||
For Period end: | 9/21/22 | 4, DEF 14A, PRE 14A | ||
List all Filings |